Mode
Text Size
Log in / Sign up

Asthma

Part of Lung Diseases, Obstructive

Subtypes of Asthma

Acute exacerbation of bronchial asthma 1 Cough variant asthma 1 Difficult-to-Control Asthma 1 Viral Asthma Exacerbations 1 Psychological stress-induced asthma 0

92 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Asthma

793 trials tracked for Asthma: 333 in phase 3 or 4 and 115 with published results. The most-cited published study has 15632 citations.

793Trials tracked
333Phase 3 & 4
0Recruiting
115With published results
Phase distribution
Phase 4 108 Phase 3 225 Phase 2 191 Phase 1 50 Other / NA 219
  1. Phase 3 Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma Completed · 15,632 cited
  2. Phase 3 Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest) Completed · 1,916 cited
  3. Phase 3 Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma Completed · 1,152 cited
  4. Phase 3 Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy Completed · 1,035 cited
  5. Phase 3 A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma. Completed · 632 cited
  6. Phase 3 A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma Completed · 511 cited
Show 44 more trials
  1. Phase 3 A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed · 425 cited
  2. Phase 3 Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Completed · 382 cited
  3. Phase 3 A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA Completed · 309 cited
  4. Phase 3 MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects Completed · 297 cited
  5. Phase 3 Individualized Therapy For Asthma in Toddlers Completed · 296 cited
  6. Phase 3 Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids. Completed · 265 cited
  7. Phase 3 TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER) Completed · 205 cited
  8. Phase 3 Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma Completed · 173 cited
  9. Phase 3 A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. Completed · 173 cited
  10. Phase 3 Study on Foster Efficacy Maintenance and Reliever vs Foster Maintenance + Salbutamol Reliever in Asthmatics (MART2) Completed · 171 cited
  11. Phase 3 A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Completed · 165 cited
  12. Phase 3 Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma Completed · 157 cited
  13. Phase 3 Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations Completed · 143 cited
  14. Phase 3 Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist Completed · 139 cited
  15. Phase 3 Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma Completed · 139 cited
  16. Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma Completed · 138 cited
  17. Phase 3 Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma Completed · 138 cited
  18. Phase 4 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old Completed · 137 cited
  19. Phase 4 A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab Completed · 136 cited
  20. Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma Completed · 122 cited
  21. Phase 3 Steroids In Eosinophil Negative Asthma Completed · 122 cited
  22. Phase 3 A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma Completed · 118 cited
  23. Phase 3 An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma Completed · 116 cited
  24. Phase 3 Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype Completed · 116 cited
  25. Phase 3 A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype Completed · 116 cited
  26. Phase 3 Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients Completed · 114 cited
  27. Phase 3 A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents Completed · 108 cited
  28. Phase 3 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. Completed · 96 cited
  29. Phase 3 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. Completed · 96 cited
  30. Phase 3 The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma Completed · 91 cited
  31. Phase 3 A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Completed · 88 cited
  32. Phase 3 A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed · 88 cited
  33. Phase 3 Acetaminophen Versus Ibuprofen in Children With Asthma Completed · 80 cited
  34. Phase 4 Long-acting Beta Agonist Step Down Study Completed · 70 cited
  35. Phase 3 AZMATICS: AZithroMycin/Asthma Trial In Community Settings Completed · 69 cited
  36. Phase 4 Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial Completed · 67 cited
  37. Phase 3 Best African American Response to Asthma Drugs Completed · 67 cited
  38. Phase 4 The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma Completed · 66 cited
  39. Phase 4 A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects Completed · 64 cited
  40. Phase 3 Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT) Completed · 64 cited
  41. Phase 3 Asthma Action at Erie Trial Completed · 61 cited
  42. Phase 3 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Completed · 55 cited
  43. Phase 3 A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma Completed · 50 cited
  44. Phase 3 Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion) Completed · 50 cited

Showing the 50 most-cited and recently-updated of 793 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Asthma: what the trials found

A quality improvement (QIP) intervention significantly increased the proportion of patients with an ICS-based maintenance and/or reliever treatment (571 vs 723, p<0.0001) and the proportion with well-controlled asthma (ACQ-5 ≤0.75) at week 48 (354 vs 641) 1. CHF 5993 200/6/12.5 µg improved pre-dose FEV1 at week 26 (0.229 L vs 0.157 L, p=0.003) and peak FEV1 (0.522 L vs 0.417 L, p<0.001) compared to placebo, but did not significantly reduce moderate/severe exacerbation rates (1.726 vs 1.963, p=0.110) 2. Salbutamol reduced the cumulative number of patients with severe exacerbations (11 vs 18 at week 1, p<0.001) and the annualized rate per 100 patients (17.61 vs 26.77, p<0.001) 3. Depemokimab did not significantly reduce the annualized rate of clinically significant exacerbations (0.57 vs 0.49, p=0.079) 4. CHF1535 200/6 µg pMDI improved morning PEF (16.45 L/min vs -3.63 L/min, p<0.001) and evening PEF (15.25 vs -4.29, p<0.001) 5. Beclomethasone/formoterol 100/6 µg did not significantly change VAS perceptions of asthma (2.68 vs 1.63, p=0.385) 6. BFF MDI 320/9.6 μg improved FEV1 AUC0-3h at week 24 (0.276 L vs 0.240 L, p<0.0001), morning pre-dose trough FEV1 (0.125 L vs 0.099 L, p=0.0447), and onset of action at 5 minutes on day 1 (0.236 L vs 0.184 L, p<0.0001) 7. BFF MDI 160/9.6 μg BID improved FEV1 AUC0-3h at week 12 (0.309 L vs 0.109 L, p<0.0001), morning pre-dose trough FEV1 (0.143 L vs 0.060 L, p=0.0096), and onset of action at 5 minutes (0.179 L vs 0.026 L, p<0.0001) 8. PT027 was non-inferior to placebo in mannitol challenge FEV1 AUC (638.7 vs 657.9) but not superior (624.2 vs 657.9, p=0.762) 9. Depemokimab safety data showed adverse events in 147 vs 301 patients, serious AEs in 21 vs 38, and neutralizing antibodies in 0 vs 5 10. Ipratropium bromide reduced hospital admissions (6 vs 15) and improved PROMIS Asthma Impact Scale (32 vs 22.5) 11. Ipratropium bromide also improved FEV1 percent change post-ipratropium (10.8%, p=0.032) 20.

Recent results — preliminary, needs further review

  • CHF 5259 12.5 µg + Qvar improved FEV1 AUC0-12h on day 42 (2.470 vs 2.373, p<0.001) and peak FEV1 (0.394 vs 0.278, p<0.001) 12.
  • CHF 5259 plus Foster 100/6 µg improved FEV1 AUC0-12h on day 42 (2.327 vs 2.332, p<0.001) and peak FEV1 (0.438 vs 0.463, p<0.001) 13.
  • MCT did not significantly change FEV1 percent predicted (65.6 vs 66.0, p=0.447) or ACQ-6 (1.8 vs 1.6, p=0.232), but reduced CompEx events per year (1.0 vs 2.7, p=0.014) 14.
  • Amlitelimab did not significantly reduce severe exacerbation rate (0.598 vs 0.463, p=0.3626) or improve FEV1 (0.09 vs 0.14, p=0.3615) or ACQ-5 (-0.83 vs -1.07, p=0.1579) 15.
  • Hyperpolarized 129XeMRI did not significantly change neutrophil percentage (57.3 vs 55.4, p=0.53) or eosinophil percentage (2.6 vs 2.8, p=0.76) 16.

For the clinician treating this condition

  • QIP interventions can significantly improve ICS-based maintenance/reliever use and asthma control 1.
  • Several ICS/LABA combinations (CHF 5993, CHF1535, BFF MDI) improve lung function (FEV1, PEF) and onset of action 2578.
  • Salbutamol reduces severe exacerbation rates, while depemokimab did not show significant benefit in exacerbation reduction 34.

AI synthesis of 17 cited trials, updated Jun 15, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about Asthma

Can high ferritin levels predict acute asthma attacks in children?

High ferritin levels are linked to a higher risk of acute asthma attacks in children, but vitamin D levels do not show a clear benefit for lung function.

Full answer →
What early-life exposures might increase the risk of childhood asthma?

Early-life exposures linked to higher childhood asthma risk include antibiotics, phthalates, prenatal cleaning products, tobacco smoke, air pollution, preterm birth, rapid weight gain, and gut/airway microbiome changes.

Full answer →
What clinical remission definition do experts suggest for severe asthma?

Experts suggest clinical remission in severe asthma means no exacerbations, no oral corticosteroids, good symptom control, and stable or optimal lung function.

Full answer →
Does biologic therapy improve asthma control for patients with severe asthma?

Yes, biologic therapy significantly improves asthma control for patients with severe asthma, reducing exacerbations and improving symptoms and lung function.

Full answer →
What are the lung function goals for patients with severe asthma?

Lung function goals for severe asthma focus on achieving optimal individual FEV1 and maintaining stability, rather than normal values, as part of clinical remission.

Full answer →
Is tezepelumab a treatment option for severe asthma patients with low inflammation?

Yes, tezepelumab is approved for severe asthma regardless of inflammation type, including low type 2 inflammation, though benefit may be smaller in these patients.

Full answer →
Can switching asthma biologics help reduce severe asthma attacks?

Switching asthma biologics often reduces severe asthma attacks, improves lung function, and lowers the need for oral steroids, though the specific benefit depends on a patient's inflammation type.

Full answer →
Does nurse-led rehabilitation consultation help improve my asthma control in primary care?

Yes, a 2023 trial found that a nurse-led structured rehabilitation consultation significantly improved asthma control, quality of life, and patient enablement in primary care compared to usual nursing care.

Full answer →
See all 10 questions about Asthma →